Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
复制标题
DOI：
10.1159/000442092
复制
发表时间：
2016-01-01
期刊：
影响因子：
5
通讯作者：
Takeshima, Yukio
中科院分区：
文献类型：
--
作者：
Kushitani, Kei;Amatya, Vishwa Jeet;Takeshima, Yukio
目的：上皮样间皮瘤（EM）和反应性间皮增生（RMH）之间的组织学鉴别诊断并不总是那么简单。本研究的目的是寻找新的免疫组织化学标记物来区分 EM 和 RMH。方法：我们通过实时 RT-PCR 阵列分析以及对显着基因表达进行聚类来评估和比较 EM 和 RMH 中凋亡相关基因的表达。对 81 例 EM 和 55 例 RMH 中的 Noxa 表达进行免疫组织化学染色和统计分析，并与其他先前报道的抗体（如 Desmin、EMA、GLUT-1、IMP-3 和 CD146）的效用进行比较。结果：RTPCR 阵列分析发现，与 RMH 相比，EM 中的 Noxa mRNA 表达水平有所增加。在免疫组织化学分析中，Noxa 作为 EM 阳性标记物区分 EM 和 RMH 的敏感性为 69.0%，特异性为 93.6%，阳性预测值为 93.0%，这些值与 IMP-3 几乎相似。结论：Noxa是一个特异性较高的标志物，可用于区分EM和RMH。这将是对当前用于 EM 和 RMH 鉴别诊断的抗体组的有价值的补充。 (C) 2016 S. Karger AG，巴塞尔
Objectives: The histological differential diagnosis between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) is not always straightforward. The aim of the present study was to search for new immunohistochemical markers to distinguish EM from RMH. Methods: We evaluated and compared the expression of apoptosis-related genes in EM and RMH by real-time RT-PCR array analysis followed by clustering of significant gene expression. Immunohistochemical staining and statistical analysis of Noxa expression in 81 cases of EM and 55 cases of RMH were performed and compared with the utility of other previously reported antibodies such as Desmin, EMA, GLUT-1, IMP-3 and CD146. Results: Noxa mRNA expression levels were found to be increased in EM when compared to RMH by RTPCR array analysis. In the immunohistochemical analysis, Noxa showed sensitivity of 69.0%, specificity of 93.6% and positive predictive value of 93.0% as a positive marker of EM in distinguishing it from RMH, and these values were almost similar to IMP-3. Conclusion: Noxa is a marker with relatively high specificity, and can be used to distinguish EM from RMH. It would be a valuable addition to the current antibody panel used for the differential diagnosis of EM and RMH. (C) 2016 S. Karger AG, Basel